Incannex Stock Slides As $10 Million Capital Raise Funds Next Study For Sleep Apnea Treatment
Incannex Stock Slides As $10 Million Capital Raise Funds Next Study For Sleep Apnea Treatment
Vandana SinghSun, March 15, 2026 at 12:00 PM UTC
0
Incannex Healthcare Limited shares are tumbling on Thursday as the company announced a registered direct offering of $10 million.
Seeks Equity Raise Of Up To $23 Million
The clinical stage biotech company will offer 2 million shares and accompanying warrants to purchase up to 2 million shares at a combined price of $5.
If the common warrants are exercised in full for cash, the company would receive up to an additional $13 million in gross proceeds.
Don't Miss:
Fast Company Calls It a ‘Groundbreaking Step for the Creator Economy' — Investors Can Still Get In at $0.85/Share
Explore the Fire-Safe Energy Storage Company With $185M in Contracted Revenue
Incannex will use the proceeds to complete the DReAMzz Phase 2 study for IHL-42X.
Additionally, Incannex has terminated its at-the-market facility and does not intend to utilize ATM financing in the near term.
Incannex Lead Drug In Sleep Apnea
On Thursday, Incannex announced an enhanced clinical development strategy for its lead drug candidate, IHL-42X, for obstructive sleep apnea (OSA), following positive phase 2 results.
The phase 2 RePOSA trial demonstrated statistically significant improvements across key endpoints, reinforcing the therapeutic potential of IHL-42X for the treatment of obstructive sleep apnea.
Advertisement
See Also: Before the IPO: How One Company Quietly Locked Up 500+ Iconic Character Rights
The low-dose patient group of 33.3% and the high-dose group of 41.2% achieved greater than 30% reduction in apnea-hypopnea index (AHI), while 13.9% of low-dose and 14.7% of high-dose experienced reductions exceeding 50%.
Incannex Streamlined Phase 3 Program
The company’s IHL-42X received Fast Track Designation from the FDA.
The strategy includes a Phase 2 crossover dose-optimization study, which aims to refine the drug’s efficacy and strengthen its clinical data package ahead of a streamlined Phase 3 program.
Incannex plans to initiate the DReAMzz Phase 2 crossover study to evaluate alternative ratios of its active ingredients, dronabinol and acetazolamide, with expectations to begin dosing patients soon.
Read Next:
This Under-$1 Pre-IPO AI Company Is Still Open to Retail Investors — Learn More
Blue-chip art has historically outpaced the S&P 500 since 1995, and fractional investing is now opening this institutional asset class to everyday investors.
Image via Shutterstock
"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!
Get the latest stock analysis from Benzinga:
APPLE (AAPL): Free Stock Analysis Report
TESLA (TSLA): Free Stock Analysis Report
This article Incannex Stock Slides As $10 Million Capital Raise Funds Next Study For Sleep Apnea Treatment originally appeared on Benzinga.com
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Source: “AOL Money”
